Neuropathix, Inc (NPTX)
| Market Cap | 3.54M |
| Revenue (ttm) | 32,000 |
| Net Income (ttm) | -4.25M |
| Shares Out | 87.98M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 0 |
| Open | 0.0410 |
| Previous Close | 0.0410 |
| Day's Range | 0.0410 - 0.0410 |
| 52-Week Range | 0.0381 - 0.5450 |
| Beta | 1.65 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About NPTX
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild trauma...
Financial Performance
Financial StatementsNews
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization...
Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to Focus...
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
DOYLESTOWN, PA / ACCESSWIRE / August 12, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it has...
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other...
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publicati...
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharm...
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the publ...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it...
Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant
DOYLESTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the publicati...
Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate
DOYLESTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (OTCQB: NPTX), (the “Company” or "Neuropathix"), a socially responsible pain management life sciences company, announced today that i...